The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

Stephanie J. Lee, John P. Klein, Claudio Anasetti, Joseph H. Antin, Fausto R. Loberiza, Brian J. Bolwell, Charles F. Lemaistre, Mark R Litzow, David Marks, Edmund K. Waller, Marie Matlack, Sergio Giralt, Mary M. Horowitz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Various therapeutic options are available for patients with chronic myelogenous leukemia. Allogeneic stem cell transplantation, though often curative, is associated with high nonrelapse mortality and long-term morbidity, particularly when cells from unrelated donors are used. Many physicians and patients opt for a trial of interferon-α (IFN)-based therapy first, reserving transplantation for patients with inadequate response or intolerance to IFN. Data were analyzed on 740 patients receiving unrelated donor transplants for chronic myelogenous leukemia in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program to see whether IFN pretreatment compromised transplantation outcome. A total of 489 (66%) had received IFN prior to transplantation; 251 (34%) had not. Disease characteristics in the 2 groups were similar at diagnosis but at the time of transplantation, hematologic parameters and weight were lower in IFN patients and the interval between diagnosis and transplantation was longer. After adjustment for baseline covariates, no effect of IFN exposure was found on overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute or chronic graft-versus-host disease. Evaluation of effects based on duration of therapy and time off IFN prior to transplantation was limited by missing data and confounding with IFN intolerance and disease responsiveness. In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation.

Original languageEnglish (US)
Pages (from-to)3205-3211
Number of pages7
JournalBlood
Volume98
Issue number12
DOIs
StatePublished - Dec 1 2001

Fingerprint

Unrelated Donors
Hematopoietic Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Interferons
Transplantation
Transplants
Therapeutics
Bone Marrow
Survival
Mortality
Stem Cell Transplantation
Graft vs Host Disease
Grafts
Registries
Bone
Leukemia
Tissue Donors
Morbidity
Physicians

ASJC Scopus subject areas

  • Hematology

Cite this

The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. / Lee, Stephanie J.; Klein, John P.; Anasetti, Claudio; Antin, Joseph H.; Loberiza, Fausto R.; Bolwell, Brian J.; Lemaistre, Charles F.; Litzow, Mark R; Marks, David; Waller, Edmund K.; Matlack, Marie; Giralt, Sergio; Horowitz, Mary M.

In: Blood, Vol. 98, No. 12, 01.12.2001, p. 3205-3211.

Research output: Contribution to journalArticle

Lee, SJ, Klein, JP, Anasetti, C, Antin, JH, Loberiza, FR, Bolwell, BJ, Lemaistre, CF, Litzow, MR, Marks, D, Waller, EK, Matlack, M, Giralt, S & Horowitz, MM 2001, 'The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase', Blood, vol. 98, no. 12, pp. 3205-3211. https://doi.org/10.1182/blood.V98.12.3205
Lee, Stephanie J. ; Klein, John P. ; Anasetti, Claudio ; Antin, Joseph H. ; Loberiza, Fausto R. ; Bolwell, Brian J. ; Lemaistre, Charles F. ; Litzow, Mark R ; Marks, David ; Waller, Edmund K. ; Matlack, Marie ; Giralt, Sergio ; Horowitz, Mary M. / The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. In: Blood. 2001 ; Vol. 98, No. 12. pp. 3205-3211.
@article{f5f0502e00754d159887f77e8d7b1877,
title = "The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase",
abstract = "Various therapeutic options are available for patients with chronic myelogenous leukemia. Allogeneic stem cell transplantation, though often curative, is associated with high nonrelapse mortality and long-term morbidity, particularly when cells from unrelated donors are used. Many physicians and patients opt for a trial of interferon-α (IFN)-based therapy first, reserving transplantation for patients with inadequate response or intolerance to IFN. Data were analyzed on 740 patients receiving unrelated donor transplants for chronic myelogenous leukemia in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program to see whether IFN pretreatment compromised transplantation outcome. A total of 489 (66{\%}) had received IFN prior to transplantation; 251 (34{\%}) had not. Disease characteristics in the 2 groups were similar at diagnosis but at the time of transplantation, hematologic parameters and weight were lower in IFN patients and the interval between diagnosis and transplantation was longer. After adjustment for baseline covariates, no effect of IFN exposure was found on overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute or chronic graft-versus-host disease. Evaluation of effects based on duration of therapy and time off IFN prior to transplantation was limited by missing data and confounding with IFN intolerance and disease responsiveness. In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation.",
author = "Lee, {Stephanie J.} and Klein, {John P.} and Claudio Anasetti and Antin, {Joseph H.} and Loberiza, {Fausto R.} and Bolwell, {Brian J.} and Lemaistre, {Charles F.} and Litzow, {Mark R} and David Marks and Waller, {Edmund K.} and Marie Matlack and Sergio Giralt and Horowitz, {Mary M.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1182/blood.V98.12.3205",
language = "English (US)",
volume = "98",
pages = "3205--3211",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

AU - Lee, Stephanie J.

AU - Klein, John P.

AU - Anasetti, Claudio

AU - Antin, Joseph H.

AU - Loberiza, Fausto R.

AU - Bolwell, Brian J.

AU - Lemaistre, Charles F.

AU - Litzow, Mark R

AU - Marks, David

AU - Waller, Edmund K.

AU - Matlack, Marie

AU - Giralt, Sergio

AU - Horowitz, Mary M.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Various therapeutic options are available for patients with chronic myelogenous leukemia. Allogeneic stem cell transplantation, though often curative, is associated with high nonrelapse mortality and long-term morbidity, particularly when cells from unrelated donors are used. Many physicians and patients opt for a trial of interferon-α (IFN)-based therapy first, reserving transplantation for patients with inadequate response or intolerance to IFN. Data were analyzed on 740 patients receiving unrelated donor transplants for chronic myelogenous leukemia in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program to see whether IFN pretreatment compromised transplantation outcome. A total of 489 (66%) had received IFN prior to transplantation; 251 (34%) had not. Disease characteristics in the 2 groups were similar at diagnosis but at the time of transplantation, hematologic parameters and weight were lower in IFN patients and the interval between diagnosis and transplantation was longer. After adjustment for baseline covariates, no effect of IFN exposure was found on overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute or chronic graft-versus-host disease. Evaluation of effects based on duration of therapy and time off IFN prior to transplantation was limited by missing data and confounding with IFN intolerance and disease responsiveness. In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation.

AB - Various therapeutic options are available for patients with chronic myelogenous leukemia. Allogeneic stem cell transplantation, though often curative, is associated with high nonrelapse mortality and long-term morbidity, particularly when cells from unrelated donors are used. Many physicians and patients opt for a trial of interferon-α (IFN)-based therapy first, reserving transplantation for patients with inadequate response or intolerance to IFN. Data were analyzed on 740 patients receiving unrelated donor transplants for chronic myelogenous leukemia in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program to see whether IFN pretreatment compromised transplantation outcome. A total of 489 (66%) had received IFN prior to transplantation; 251 (34%) had not. Disease characteristics in the 2 groups were similar at diagnosis but at the time of transplantation, hematologic parameters and weight were lower in IFN patients and the interval between diagnosis and transplantation was longer. After adjustment for baseline covariates, no effect of IFN exposure was found on overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute or chronic graft-versus-host disease. Evaluation of effects based on duration of therapy and time off IFN prior to transplantation was limited by missing data and confounding with IFN intolerance and disease responsiveness. In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0035760886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035760886&partnerID=8YFLogxK

U2 - 10.1182/blood.V98.12.3205

DO - 10.1182/blood.V98.12.3205

M3 - Article

VL - 98

SP - 3205

EP - 3211

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -